Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.102.34
- Author:
Xin AI
1
;
Yan WANG
1
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Review
- Keywords:
Epigenomics;
Lung neoplasms;
Resistance mechanism;
Targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
DNA Methylation;
Epigenesis, Genetic;
Humans;
Lung Neoplasms/genetics*
- From:
Chinese Journal of Lung Cancer
2021;24(10):705-713
- CountryChina
- Language:Chinese
-
Abstract:
Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling, are important mechanisms of acquired resistance in targeted therapy of NSCLC. In recent years, studies have found that epigenetic modifications can effectively reverse drug resistance. Targeted therapy combined with epigenetic modifications may become a promising therapeutic strategy. Here, we review the progress of epigenetic mechanism in acquired resistance of targeted therapy in NSCLC, hoping to provide ideas for screening dominant population and overcoming resistance.
.
